ClinicalTrials.gg
CompletedNCT01313780TOPUpdated Dec 22, 2017Results posted

A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients

A Phase 4 interventional study of Oxycodone/Naloxone and Oxycodone(single compound) in Cancer, sponsored by Mundipharma Korea Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-12-22.

Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Objectives:

To prove non-inferiority of Targin compared to Oxycontin in terms of change of pain intensity

  1. Primary objective: Change of pain intensity (NRS 0-10) score (average pain over 24 hours obtained each evening) within 4 weeks
  2. Secondary objectives: Bowel Habit (worsening/no change/improving), Total dose and frequency of rescue medication, Quality of Life (QOL; EORTC QLQ-C30), Duration to need of laxative use and Adverse events
Read the detailed description

This will be a 4-week multicentre, randomized, open label, parallel group, active control study to evaluate efficacy and safety of Targin in comparison with Oxycontin in Korean patients with cancer pain who are administered weak opioid or naïve patients including patient not on the long term strong opioid medication within 3 months.

02

Conditions studied

  • Cancer

Keywords

  • cancer related pain
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 128 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Mundipharma Korea Ltd is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female cancer patients 20 years of age or older
  2. Cancer related pain that requires treatment with continuous around-the-clock strong opioid analgesic
  3. Moderate to severe pain intensity(NRS pain score 4)
  4. Opioid naïve patients or patients not treated with strong opioids(except PRN) within 4 weeks or patients who has been on weak opioids
  5. Subject who provide signed and dated written voluntary

Exclusion criteria

Exclusion Criteria:

  1. Women of , defined as all women physiologically capable of becoming pregnant. UNLESS they are:

    • women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
    • women shoes partners have been sterilized by vasectomy or other means
    • two methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
  2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test.
  3. Have previously received treatment with Targin or Oxycontin within 4weeks(28days) of screening periods(including PRN)
  4. If subjects started first cycle of chemotherapy during the 2 weeks before the screening visit or during the study, they should be excluded from the study.

    And If the chemotherapy regimen or dosage to be planned to change during the study, the subjects should be excluded from the study.

  5. Patient who is administered laxatives with stable dose for more than 1 week
  6. Patient with evidence of significant structural/functional abnormalities of GI tract which is not appropriate for oral medicine administration. Any history of to Oxycodone and Naloxone
  7. Patients with significant respiratory depression
  8. Patients with acute or severe bronchial asthma or hypercarbia
  9. Any patient who has or is suspected of having paralytic ileus
  10. Severe , pulmonary heart disease
  11. Targin product contains lactose. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take
  12. Patients with moderate and severe hepatic impairment
  13. Abnormal (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (>2.5 times the , it is allowed >5 times the upper limit of normal in case of transition in liver) or an abnormal total and/or creatinine level(s) (greater than 1.5 times the upper limit of normal)
  14. Any situation where opioids are
  15. Major surgery within 1 month prior to screening or planned surgery
  16. Mainly pain originated other than cancer or cancer related conditions (eg. Musculoskeletal pain, inflammatory pain, diabetic polyneuropathy)
  17. Patients with known or suspected unstable or spinal cord compression that may require changes in treatment throughout the duration of the study
  18. Patients with uncontrolled seizures
  19. Requiring interventional treatment for pain such as neurodestructive procedure or regional infusion
  20. With a history of alcohol abuse within 6 months of screening
  21. With a history of illicit drug abuse within 6 months of screening
  22. Patients with increased intracranial pressure
  23. In the investigator's opinion, subjects who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication
  24. Patients with myxoedema, not adequately treated hypothyroidism or Addison's disease
  25. Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine)
  26. Patients with evidence of gastrointestinal disease (e.g. paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the gastrointestinal tract (e.g. scarring, obstruction etc) either related or not related to the underlying cancer or disease progression
  27. Patients suffering from diarrhea and/or opioid withdrawal
  28. With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score
  29. Clinically significant impairment of cardiovascular, respiratory and renal function
  30. Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment
  31. Having used other drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    'Oxycodone/Naloxone'

    Trade name is Targin(fixed combination drug).

    Drug: Oxycodone/Naloxone

  • Active comparator
    Oxycodone

    Trade name is Oxycontin(single compound).

    Drug: Oxycodone(single compound)

Interventions

  • DrugOxycodone/Naloxone

    Drug pages: Oxycodone · Naloxone

    Dose and administration : Upto 40mg B.I.D per daily.

    Also known as: Targin(fixed combination drug)

  • Dose and administration : Upto 40mg B.I.D per daily.

    Also known as: Oxycontin

06

What researchers measure

Primary outcomes

  1. Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3)

    Change of pain intensity from 0(No pain) to 10(worst pain imaginable) after 4 weeks treatment .

    Time frame: 4weeks

Secondary outcomes

  1. Change in Bowel Habits.

    The change of bowel habits from baseline (Visit 1) in bowel habits at Week 4 was investigated, and was categorized as 'improved', 'unchanged', and 'worsened'.

    Time frame: 4 weeks

07

Results

Posted Oct 27, 2016

Participant flow

ITT set(Safety analysis) was 128(64:64) patients, but Missing primary efficacy data: 7 patients, Violation of inclusion/exclusion criteria: 4. So, FAS(Efficacy analysis) set population was 117(oxycodone/naloxone group: 58: Oxycodone: 59).

Participant flow — Overall Study
MilestoneOxycodone and NaloxoneOxycodone
Started5859
Completed3331
Not completed2528
Withdrew: Lack of efficacy42
Withdrew: Adverse event611
Withdrew: Withdrawal by subject28
Withdrew: Protocol violation104
Withdrew: Missing data33

Outcome measures

PrimaryChange of Pain Intensity From Baseline(visit1) to 4weeks.(visit3)

Change of pain intensity from 0(No pain) to 10(worst pain imaginable) after 4 weeks treatment .

Time frame:
4weeks
Reported as:
Mean · units on a scale
Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3)
units on a scaleOxycodone and NaloxoneOxycodone
Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3)1.586 ± 2.2171.559 ± 2.215
SecondaryChange in Bowel Habits.

The change of bowel habits from baseline (Visit 1) in bowel habits at Week 4 was investigated, and was categorized as 'improved', 'unchanged', and 'worsened'.

Time frame:
4 weeks
Reported as:
Number · participants
Change in Bowel Habits.
participantsOxycodone and NaloxoneOxycodone
Unchanged3120
worsened711
Improved55

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxycodone and Naloxone—15/64 (23.4%)55/64 (85.9%)
Oxycodone—28/64 (43.8%)57/64 (89.1%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventOxycodone and NaloxoneOxycodone
pneumoniaInfections and infestations2/640/64
Glucose, serum-low (hypoglycemia)Metabolism and nutrition disorders2/640/64
PainGeneral disorders1/642/64
anaphylactic shockImmune system disorders0/641/64
leukocytosisInvestigations0/641/64
neutropeniaInvestigations1/640/64
ThrombocytopeniaInvestigations0/641/64
FeverGeneral disorders1/640/64
General condition worseGeneral disorders0/641/64
SweatingGeneral disorders0/641/64
Most frequent other events
Showing 10 of 118
Most frequent other events
EventOxycodone and NaloxoneOxycodone
ConstipationGastrointestinal disorders30/6435/64
NauseaGastrointestinal disorders10/6418/64
DizzinessNervous system disorders6/6414/64
AnorexiaGastrointestinal disorders8/644/64
VomitingGastrointestinal disorders8/647/64
DiarrheaGastrointestinal disorders4/641/64
Dyspnea (shortness of breath)Respiratory, thoracic and mediastinal disorders0/644/64
Fatigue (asthenia, lethargy, malaise)General disorders3/643/64
InsomniaNervous system disorders3/641/64
Pruritus/itchingSkin and subcutaneous tissue disorders2/643/64

Baseline characteristics

Age, Customized
Age, Customized(participants)Oxycodone and NaloxoneOxycodoneTotal
<39years134
40~49years7512
50~59years191736
60~69 years142337
70~79 years171128
Sex: Female, Male
Sex: Female, Male(Participants)Oxycodone and NaloxoneOxycodoneTotal
Female152035
Male433982
Region of Enrollment
Region of Enrollment(participants)Oxycodone and NaloxoneOxycodoneTotal
Korea, Republic of5859117
08

Study locations

1 site
  • AMC
    Seoul, Pungnap-dong 138-736, Korea, Republic of
09

References and documents

Publications

  • Lee KH, Kim TW, Kang JH, Kim JS, Ahn JS, Kim SY, Yun HJ, Eum YJ, Koh SA, Kim MK, Hong YS, Kim JE, Lee GW. Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial. Chin J Cancer. 2017 Sep 11;36(1):74. doi: 10.1186/s40880-017-0241-4. PubMed 28893309 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Oct 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2011
First posted
Mar 14, 2011
Start
May 2011
Primary completionActual
Oct 2013
CompletionActual
Jun 2014
Results first posted
Oct 27, 2016
Last update
Dec 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01313780
Responsible party
Sponsor
First posted
Mar 14, 2011
Start date
May 2011
Primary completion
Oct 2013
Completion
Jun 2014
Results posted
Oct 27, 2016
Last update
Dec 22, 2017

Study contacts

Kim, M.D
principal investigator · Asan Medical Center
Ahn, M.D
principal investigator · Samsung Medical Center
Kim, M.D
principal investigator · National Cancer Center
Kim, M.D
principal investigator · SMG-SNU Boramae Medical Center
Lee, M.D
principal investigator · Shinchone Yonsei Severance Medical Center
Kang Jugnhoon
principal investigator · Kyungsang University Hospital
Lee Kyunghee, MD
principal investigator · Youngnam Univ. Hospital
Yoon Hwanjung, MD
principal investigator · Chungnam University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Naloxone

Start the discussion